期刊文献+

药物基因组学在晚期非小细胞肺癌治疗中的应用 被引量:1

下载PDF
导出
摘要 药物基因组学以药物效应及安全性为目标,将基因的多态性与药物效应个体多样性紧密的联系在一起。药物基因组学研究不同于以往的基因研究,不是以发现新基因,阐明作用机制为目标,而是通过研究遗传因素对药物效应的影响,针对不同个体携带的基因型,给予不同的药物或剂量,以达到个体化治疗的目的。目前药物基因组学的研究主要是单核苷酸多态性(SNP)的研究,随着对药物作用机制分子水平的深入阐明,药物基因组学在抗癫痫药物、
出处 《中国药师》 CAS 2010年第4期491-493,共3页 China Pharmacist
  • 相关文献

参考文献1

二级参考文献14

  • 1Risch NJ. Searching for genetic determinants in the new millennium [J]. Nature,2000,405:847- 856.
  • 2Weinshilboum R. Inheritance and drug response [J]. N Engl J Med,2003,348:529- 537.
  • 3Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy [J]. Cancer Treat Rev,1998,24:331- 344.
  • 4Rosell R,Lord RV,Taron M,et al. DNA repair and cisplatin resistance in non-small-cell lung cancer [J]. Lung Cancer,2002,38:217- 227.
  • 5Lunn RM,Langlois RG,Hsieh LL,et al. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency [J]. Cancer Res,1999,59:2557- 2561.
  • 6Schiller JH,Harrington D,Belani CP,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer [J]. N Engl J Med,2002,346:92- 98.
  • 7Zatloukal P,Petruzelka L,Zemanova M,et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage Ⅲ b and Ⅳ non-small cell lung cancer: a phase Ⅲ randomized trial [J]. Lung Cancer,2003,41:321- 331.
  • 8Xing D,Qi J,Lin D,et al. Polymorphisms of DNA repair genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population [J]. Int J Cancer,2002,100:600- 605.
  • 9Xing D,Tan W,Lin D. Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population(review)[J].Oncol Rep,2003,10:1615- 1623.
  • 10Duell EJ,Millikan RC,Pittman GS,et al. Polymorphisms in the DNA repair gene XRCC1 and breast cancer [J]. Cancer Epidemiol Biomarkers Prev,2001,10:217- 222.

共引文献55

同被引文献49

  • 1周喆,岳利多,覃文新.药物基因组学对癌症化疗的启示[J].生命科学,2006,18(1):67-74. 被引量:3
  • 2王立峰,钱晓萍,刘宝瑞.药物遗传学和药物基因组学在肿瘤治疗中的应用[J].世界华人消化杂志,2006,14(3):318-323. 被引量:13
  • 3Efferth T,Volm M. Pharmacogenetics for individualized cancer chemotherapy[J].Pharmacology & Therapeutics,2005,(02):155-176.
  • 4Richmond ES,Dunn D. Biomarkers:an overview for oncology nurses[J].Seminars in Oncology Nursing,2012,(02):87-92.
  • 5Gao B,Klumpen H J,Gumey H. Dose calculation of anticancer drugs[J].Expert Opinion on Drug Metabolism and Toxicology,2008,(10):1307-1319.
  • 6van Schaik RH. CYP450 pharmacogenetics for personalizing cancer therapy[J].Drug Resistance Updates,2008,(03):77-98.
  • 7Schimer M,Toliat MR,Haberl M. Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations[J].PHARMACOGENETICS AND GENOMICS,2006,(01):59-71.
  • 8Aplenc R,Glatfelter W,Han P. CYP3A Genotypes and treatment response in paediatric acute lymphoblastic leukaemia[J].British Journal of Haematology,2003,(02):240-244.
  • 9Fujita K,Sasaki Y. Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy[J].Current Drug Metabolism,2007,(06):554-562.
  • 10Marsh S,Somlo G,Li X. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer[J].Pharmacogenomics,2007,(05):362-365.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部